Available Technologies

No technologies match these criteria.
Schedule UC TechAlerts to receive an email when technologies are published that match this search. Click on the Save Search link above

Find technologies available for licensing from UCSF.

Novel Methodology To Convert Magnetic Resonance Imaging Scan Data To Be Used In Proton Beam Therapy

This invention is a novel model that uses magnetic resonance imaging (MRI) information to more accurately determine the irradiation area using proton beam therapy (PBT) for oncological treatment.

Percutaneous Arteriovenous Fistula For Dialysis Access

This implantable medical device can be used to create an arteriovenous fistula (AVF) percutaneously, in a clinic based procedure. The AVF improves clinical outcomes for  patients  on hemodialysis.

Structurally Validated Anti-avß8 Antibodies for Targeting TGFß for Immunotherapy

This invention provides highly efficient antibodies whose epitopes and mechanism of action have been structurally defined against integrin αvβ8. These antibodies have been designed to be used as therapeutic for cancer. Other antibodies have been designed as companion diagnostic tools.

A New Class of mTOR Inhibitors for Targeted Treatment of Anti-cancer, Anti-aging, and Anti-autism and Regenerative Medicine

Novel hybrid inhibitors of mTOR (mammalian target of rapamycin kinase) that selectively target mTORC1 (mammalian target of rapamycin complex 1) and completely inhibit downstream phosphorylation of its substrates for cancer treatment as well as regenerative medicine, aging and autism (TSC mutations).

Novel Covalent Inhibitors Of GTP And GDP-bound RAS

This invention describes a novel class of direct Ras inhibitors that bind and inhibit this oncogene in its GTP and GDP-bound states.


Pseudomonas aeruginosais an opportunistic bacterial pathogen responsible for 10% of all nosocomial (hospital-acquired) infections, a leading cause of nosocomial pneumonia in general patient populations, and the leading cause in intensive care patient populations. Since Pseudomonas is often resistant to antibiotics, an infection is life-threatening for compromised individuals such as burn victims, AIDS patients, and patients with cystic fibrosis. Respiratory failure, the leading cause of cystic fibrosis-associated death, results from chronic Pseudomonas infections that lead to lung damage as bacterial toxins attack lung epithelia. This damage then allows the infection to spread beyond the lungs. A secretion/intoxication system present on the bacterial surface transports toxins directly into epithelial cells, and a well-documented inhibition of this system through blockade of the bacterial toxin transport component PcrV provides demonstrable protection against lung injury and increased survival in animal models. Researchers at the University of California, San Francisco have shown that the PcrV protein is a highly effective vaccination agent against Pseudomonas, whether administered before or after infection.


This invention uses sequencing of microbiota community for diagnosis and treatment of lung and nasal dysbiosis.

Sealed Nanostraw Microdevices For Oral Drug Delivery

This invention is a nanostraw device that is built upon microdevice technology for oral drug delivery. It is the first example of a microdevice for oral drug delivery, with the drug sealed in by a semi-permeable membrane for (1) in-solution drug loading, and tunable drug release, (2) increased bioadhesion for prolonged drug exposure, and (3) protection of drug from outside biomolecules.

These technologies are part of the UC QuickStart program.